Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020555 | 1.00 | IL1B (0.66) | IL1BP2RX7 | |
| SCHEMBL1020097 | 0.89 | IL1B (0.67) | IL1BP2RX7 | |
| SCHEMBL1019692 | 0.89 | IL1B (0.65) | IL1BP2RX7 | |
| SCHEMBL1019587 | 0.89 | IL1B (0.65) | IL1BP2RX7 | |
| SCHEMBL1020693 | 0.88 | IL1B (0.52) | IL1BP2RX7 | |
| SCHEMBL1018210 | 0.88 | IL1B (0.52) | IL1BP2RX7 | |
| SCHEMBL13673108 | 0.88 | IL1B (0.51) | IL1BP2RX7 | |
| SCHEMBL1020278 | 0.88 | IL1B (0.51) | IL1BP2RX7 | |
| SCHEMBL1018827 | 0.88 | CNR1 (0.55) | IL1BP2RX7 | |
| SCHEMBL1019256 | 0.88 | IL1B (0.51) | IL1BP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232290-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-07-31 | — | — | US | claimed |
| EP-2105164-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-01-12 | — | — | EP | claimed |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-12-17 | — | — | US | claimed |
| WO-2009118175-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-10-01 | — | — | WO | claimed |
| EP-2105164-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2009-09-30 | — | — | EP | claimed |
| US-8815892-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815892-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815892-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8569334-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569334-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569334-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-10-29 | — | — | US | disclosed |
| US-20130197046-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-08-01 | — | — | US | disclosed |
| CN-102046240-A | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG | 2011-05-04 | — | — | CN | disclosed |
| EP-2105164-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2009118175-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118175-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-10-01 | — | — | WO | disclosed |
| EP-2105164-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2009-09-30 | — | — | EP | disclosed |
| EP-2105164-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2009-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197046-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX7, P2RX2 | IL1B 583/4885P2RX7 2/4885 |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX7, P2RX2 | IL1B 583/4885P2RX7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.